{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:01:11Z","timestamp":1761872471341,"version":"build-2065373602"},"reference-count":99,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clml.2023.07.008","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T18:49:18Z","timestamp":1690570158000},"page":"800-814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Application of 18F-FDG-PET Quantification in Hematological Malignancies: Emphasizing Multiple Myeloma, Lymphoma and Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"23","author":[{"given":"Mahdi","family":"Zirakchian Zadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.07.008_bib0001","first-page":"885","article-title":"Procedure guideline for tumor imaging with 18F-FDG PET\/CT 1.0","volume":"47","author":"Delbeke","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0002","series-title":"StatPearls","article-title":"Fludeoxyglucose (18F)","author":"Ashraf","year":"2023"},{"key":"10.1016\/j.clml.2023.07.008_bib0003","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/j.seminoncol.2010.11.012","article-title":"Metabolic positron emission tomography imaging in cancer detection and therapy response","volume":"38","author":"Zhu","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2023.07.008_bib0004","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.07.008_bib0005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/MNM.0000000000001528","article-title":"A review of different methods used for quantification and assessment of FDG-PET\/CT in multiple myeloma","volume":"43","author":"Zirakchian Zadeh","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clml.2023.07.008_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current methods to define metabolic tumor volume in positron emission tomography: which one is better?","volume":"52","author":"Im","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0007","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-022-05977-5","article-title":"Reproducibility of [18F]FDG PET\/CT liver SUV as reference or normalisation factor","volume":"50","author":"Zwezerijnen","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0008","first-page":"204","article-title":"Variation and repeatability of measured standardized uptake values depending on actual values: a phantom study","volume":"7","author":"Kaneta","year":"2017","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0009","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnmt.115.161745","article-title":"Influence of statistical fluctuation on reproducibility and accuracy of SUVmax and SUVpeak: a phantom study","volume":"43","author":"Akamatsu","year":"2015","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.clml.2023.07.008_bib0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13550-019-0569-7","article-title":"SUV variability in EARL-accredited conventional and digital PET","volume":"9","author":"Koopman","year":"2019","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.clml.2023.07.008_bib0011","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0012","first-page":"257","article-title":"Correlation of whole-bone marrow dual-time-point (18)F-FDG, as measured by a CT-based method of PET\/CT quantification, with response to treatment in newly diagnosed multiple myeloma patients","volume":"10","author":"Zirakchian Zadeh","year":"2020","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0013","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/MNM.0000000000001573","article-title":"Prognostic significance of conventional and volumetric PET parameters with and without partial volume correction in the assessment of head and neck squamous cell carcinoma","volume":"43","author":"Zirakchian Zadeh","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clml.2023.07.008_bib0014","first-page":"248","article-title":"Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease","volume":"9","author":"Seraj","year":"2019","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0015","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","article-title":"Assessment of total lesion glycolysis by (18)F FDG PET\/CT significantly improves prognostic value of GEP and ISS in Myeloma","volume":"23","author":"McDonald","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.07.008_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194396","article-title":"Total lesion glycolysis improves tumor burden evaluation and risk assessment at diagnosis in hodgkin lymphoma","volume":"10","author":"Herraez","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0017","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7528971","article-title":"Prognostic value of MTV and TLG of (18)F-FDG PET in patients with stage I and II non-small-cell lung cancer: a meta-analysis","volume":"2021","author":"Wen","year":"2021","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0018","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00330-020-07412-5","article-title":"Critical role of PET\/CT-based novel quantitative techniques for assessing global disease activity in multiple myeloma and other hematological malignancies: why it is time to abandon reliance on examining focal lesions","volume":"31","author":"Taghvaei","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clml.2023.07.008_bib0019","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2016.69.3747","article-title":"Metabolic tumor volume in lymphoma: hype or hope?","volume":"34","author":"Sch\u00f6der","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.07.008_bib0020","first-page":"190","article-title":"Quantification of the total bone marrow activity with FDG-PET in multiple myeloma before and after treatment: comparison with a control group","volume":"58","author":"Zadeh","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0021","first-page":"1017","article-title":"Global assessment of PET tracer uptake in the skeleton using CT segmentation: a novel approach to quantification of disease activity and whole body metabolism","volume":"58","author":"Acosta-Montenegro","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0022","doi-asserted-by":"crossref","first-page":"16429","DOI":"10.1038\/s41598-019-52740-2","article-title":"Proposal for a quantitative (18)F-FDG PET\/CT metabolic parameter to assess the intensity of bone involvement in multiple myeloma","volume":"9","author":"Takahashi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2023.07.008_bib0023","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cpet.2019.03.004","article-title":"Evolving roles of fluorodeoxyglucose and sodium fluoride in assessment of multiple myeloma patients: introducing a novel method of PET quantification to overcome shortcomings of the existing approaches","volume":"14","author":"Zadeh","year":"2019","journal-title":"PET Clin"},{"key":"10.1016\/j.clml.2023.07.008_bib0024","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1007\/s00259-020-04768-0","article-title":"Comparison of (18)F-sodium fluoride uptake in the whole bone, pelvis, and femoral neck of multiple myeloma patients before and after high-dose therapy and conventional-dose chemotherapy","volume":"47","author":"Zirakchian Zadeh","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"year":"2010","series-title":"Myeloma Bone Disease","author":"Roodman","key":"10.1016\/j.clml.2023.07.008_bib0025"},{"key":"10.1016\/j.clml.2023.07.008_bib0026","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: from biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.008_bib0027","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.07.008_bib0028","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.pop.2016.07.012","article-title":"Lymphoma","volume":"43","author":"Mugnaini","year":"2016","journal-title":"Prim Care"},{"key":"10.1016\/j.clml.2023.07.008_bib0029","first-page":"608","article-title":"Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET\/CT examinations","volume":"46","author":"Brix","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0030","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4103\/0971-3026.125626","article-title":"FDG-PET\/CT in lymphoma","volume":"23","author":"D'Souza","year":"2013","journal-title":"Indian J Radiol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0031","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2007-07-101899","article-title":"Imaging in staging of malignant lymphoma: a systematic review","volume":"111","author":"Kwee","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.008_bib0032","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1007\/s00259-003-1159-4","article-title":"Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma","volume":"30","author":"Vinnicombe","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0033","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1200\/JCO.2006.06.5946","article-title":"Commonly used imaging techniques for diagnosis and staging","volume":"24","author":"Barentsz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.07.008_bib0034","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00247-009-1434-z","article-title":"Estimated cumulative radiation dose from PET\/CT in children with malignancies: a 5-year retrospective review","volume":"40","author":"Chawla","year":"2010","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.clml.2023.07.008_bib0035","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/annonc\/mdp030","article-title":"High SUV uptake on FDG\u2013PET\/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG\u2013PET\/CT staging in lymphoma","volume":"20","author":"Ngeow","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2023.07.008_bib0036","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Sch\u00f6der","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.07.008_bib0037","first-page":"1267","article-title":"Detection of Richter's transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0038","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3109\/10428194.2013.869801","article-title":"Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"55","author":"Conte","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.07.008_bib0039","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/10428194.2013.802313","article-title":"2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation","volume":"55","author":"Papaj\u00edk","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.07.008_bib0040","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2014-03-563700","article-title":"FDG\/PET in CLL today","volume":"123","author":"Molica","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.008_bib0041","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.07.008_bib0042","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3324\/haematol.2019.240564","article-title":"The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.07.008_bib0043","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.008_bib0044","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.008_bib0045","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3390\/cancers12092532","article-title":"Glucose metabolism quantified by SUVmax on baseline FDG-PET\/CT predicts survival in newly diagnosed multiple myeloma patients: combined harmonized analysis of two prospective phase III trials","volume":"12","author":"Michaud-Robert","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2023.07.008_bib0046","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.008_bib0047","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fmed.2019.00069","article-title":"Interest of pet imaging in multiple myeloma","volume":"6","author":"Jamet","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clml.2023.07.008_bib0048","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00259-020-05078-1","article-title":"A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy","volume":"48","author":"Paschali","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0049","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.7150\/jca.24836","article-title":"A predicting model of bone marrow malignant infiltration in (18)F-FDG PET\/CT images with increased diffuse bone marrow FDG uptake","volume":"9","author":"Zhou","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.clml.2023.07.008_bib0050","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/10428190903440953","article-title":"SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma","volume":"51","author":"Watanabe","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.07.008_bib0051","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/MNM.0000000000000496","article-title":"Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma","volume":"37","author":"Huang","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clml.2023.07.008_bib0052","first-page":"1419","article-title":"SUVmax cut-off between aggressive and indolent non-Hodgkin lymphoma in non-time of flight FDG PET\/CT and time of flight FDG PET\/CT","volume":"59","author":"ALOBTHANI","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0053","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2967\/jnumed.114.145029","article-title":"Update on time-of-flight PET imaging","volume":"56","author":"Surti","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0054","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.18632\/oncotarget.13873","article-title":"Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18F-FDG PET\/CT in extra-nodal NK\/T-cell lymphoma","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2023.07.008_bib0055","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2023.07.008_bib0056","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1038\/s41375-022-01713-y","article-title":"Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial","volume":"36","author":"Seifert","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.07.008_bib0057","series-title":"Imaging in Dermatology","first-page":"485","article-title":"Chapter 35\u2014imaging evaluation of cutaneous lymphoma using functional and structural imaging","author":"Fardin","year":"2016"},{"key":"10.1016\/j.clml.2023.07.008_bib0058","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.2019001091","article-title":"Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study","volume":"135","author":"Mir","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.008_bib0059","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.07.008_bib0060","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2967\/jnumed.111.101733","article-title":"Noise considerations for PET quantification using maximum and peak standardized uptake value","volume":"53","author":"Lodge","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0061","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.2967\/jnumed.107.050187","article-title":"Treatment monitoring by 18F-FDG PET\/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors","volume":"49","author":"Benz","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0062","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1148\/rg.2016150102","article-title":"Role of optimal quantification of FDG PET imaging in the clinical practice of radiology","volume":"36","author":"Ziai","year":"2016","journal-title":"Radiographics"},{"key":"10.1016\/j.clml.2023.07.008_bib0063","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1007\/s00330-014-3222-x","article-title":"Variability of average SUV from several hottest voxels is lower than that of SUVmax and SUVpeak","volume":"24","author":"Laffon","year":"2014","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clml.2023.07.008_bib0064","first-page":"1396","article-title":"A multi-center phantom study towards harmonization of FDG-PET: variability in maximum and peak SUV in relation to image noise","volume":"61","author":"Shimada","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0065","first-page":"2016","article-title":"Impact of time-of-flight reconstruction on maximum standard uptake values in FDG PET\/CT scanning","volume":"51","author":"Ruter","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0066","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejrad.2013.09.030","article-title":"Influences of point-spread function and time-of-flight reconstructions on standardized uptake value of lymph node metastases in FDG-PET","volume":"83","author":"Akamatsu","year":"2014","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.clml.2023.07.008_bib0067","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","article-title":"Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma","volume":"53","author":"Fonti","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0068","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","author":"Kanoun","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0069","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1080\/10428194.2021.1941933","article-title":"Value of baseline and end of chemotherapy (18)F-FDG PET\/CT in pediatric patients with Burkitt lymphoma","volume":"62","author":"Xiao","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.07.008_bib0070","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.3390\/jcm10194396","article-title":"Total lesion glycolysis improves tumor burden evaluation and risk assessment at diagnosis in Hodgkin lymphoma","volume":"10","author":"Herraez","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0071","first-page":"1380","article-title":"Pretherapy metabolic tumor burden (MTV) may risk-stratify lymphoma patients: comparison with early metabolic response","volume":"53","author":"Kostakoglu","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0072","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-030-65768-0_7","article-title":"Non-Hodgkin lymphoma metabolism","volume":"1311","author":"Kirsch","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clml.2023.07.008_bib0073","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-Cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.07.008_bib0074","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/bloodadvances.2019001201","article-title":"SAKK38\/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model","volume":"4","author":"Ceriani","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.07.008_bib0075","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/bloodadvances.2020001816","article-title":"High metabolic heterogeneity on baseline 18FDG-PET\/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma","volume":"4","author":"Senjo","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.07.008_bib0076","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood-2018-01-826958","article-title":"Metabolic heterogeneity on baseline 18FDG-PET\/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma","volume":"132","author":"Ceriani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.008_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.713577","article-title":"Tumor burden measured by 18F-FDG PET\/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-Cell therapy in Non-Hodgkin lymphoma","volume":"11","author":"Hong","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2023.07.008_bib0078","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high\u2013tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.07.008_bib0079","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12149-019-01354-9","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in mantle cell lymphoma","volume":"33","author":"Albano","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00259-018-4173-2","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in Burkitt lymphoma","volume":"46","author":"Albano","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0081","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12149-018-1274-8","article-title":"Prognostic role of pretreatment 18F-FDG PET\/CT in primary brain lymphoma","volume":"32","author":"Albano","year":"2018","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0082","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/RLU.0000000000002879","article-title":"Prognostic value of baseline total metabolic tumor volume measured on FDG PET in patients with Richter syndrome","volume":"45","author":"Pontoizeau","year":"2020","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0083","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/j.clml.2020.12.003","article-title":"2-[18F]-FDG PET\/CT role in detecting Richter transformation of chronic lymphocytic leukemia and predicting overall survival","volume":"21","author":"Albano","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"10.1016\/j.clml.2023.07.008_bib0084","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/radiation1010006","article-title":"The role of 2-[18F]-FDG PET\/CT in detecting richter transformation in chronic lymphocytic leukemia: a systematic review","volume":"1","author":"Albano","year":"2021","journal-title":"Radiation"},{"key":"10.1016\/j.clml.2023.07.008_bib0085","first-page":"151","article-title":"Prognostic significance of (18)F-sodium fluoride in newly diagnosed multiple myeloma patients","volume":"10","author":"Zadeh","year":"2020","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0086","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","article-title":"Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma","volume":"126","author":"Ceriani","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.008_bib0087","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0969-8051(00)00155-4","article-title":"Anatomy of SUV","volume":"27","author":"Huang","year":"2000","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.clml.2023.07.008_bib0088","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.3390\/cancers15092494","article-title":"18F-FDG PET\/CT maximum tumor dissemination (Dmax) in lymphoma: a new prognostic factor?","volume":"15","author":"Albano","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2023.07.008_bib0089","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","article-title":"18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome","volume":"61","author":"Cottereau","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2023.07.008_bib0090","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hon.3049","article-title":"Dmax: a simple and reliable PET\/CT-derived new biomarker of lymphoma outcome?","volume":"40","author":"Ceriani","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2023.07.008_bib0091","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jha2.432","article-title":"Blood-circulating EV-miRNAs, serum TARC, and quantitative FDG-PET features in classical Hodgkin lymphoma","volume":"3","author":"Drees","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2023.07.008_bib0092","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MNM.0000000000001165","article-title":"Computed tomography-based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma","volume":"41","author":"Takahashi","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clml.2023.07.008_bib0093","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.008_bib0094","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s13244-010-0062-3","article-title":"Causes and imaging features of false positives and false negatives on F-PET\/CT in oncologic imaging","volume":"2","author":"Long","year":"2011","journal-title":"Insights Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0095","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3804673","article-title":"The value of diffuse splenic and hepatic (18)F-FDG uptake on PET\/CT in diagnosing patients with anemia","volume":"2022","author":"Deng","year":"2022","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0096","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The intricate role of CXCR4 in cancer","volume":"124","author":"Chatterjee","year":"2014","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.clml.2023.07.008_bib0097","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","article-title":"CXCR4-targeted theranostics in oncology","volume":"49","author":"Buck","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0098","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.07.008_bib0099","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41375-023-01824-0","article-title":"Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma","volume":"37","author":"Leipold","year":"2023","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:47Z","timestamp":1761871427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":99,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2152265023002276"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.07.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Application of 18F-FDG-PET Quantification in Hematological Malignancies: Emphasizing Multiple Myeloma, Lymphoma and Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}